New research shows GLP-1 drugs may be linked to a twofold increase in the risk of wet AMD among people with diabetes.

Pharmacovigilance Risk Assessment Committee (PRAC) has concluded its review of semaglutide-containing medicines, confirming a ...

The European Medicines Agency (EMA) has warned that popular weight-loss and diabetes drugs containing semaglutide — including ...

Semaglutide, widely used to treat diabetes and obesity, was associated with more than double the risk of developing ...

Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...

Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...

A European health authority has found that medications containing semaglutide—such as Ozempic, Wegovy, and Rybelsus—can ...

EMA’s safety committee concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus & Wegovy: Amsterdam, The Netherlands Monday, June 9, 2 ...

Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...